Michael Gelband’s Pacific Biosciences PACB Stock Holding History

Michael Gelband’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.6K	Buy	+17,004	New	+$24.7K	﹤0.01%	1490
2025 Q3	–	Sell	-25,573	Closed	-$32K	–	1891
2025 Q2	$32K	Buy	+25,573	New	+$29.5K	﹤0.01%	1377
2023 Q1	–	Sell	-12,413	Closed	-$102K	–	2039
2022 Q4	$102K	Buy	+12,413	New	+$107K	﹤0.01%	1515
2022 Q2	–	Sell	-30,141	Closed	-$274K	–	2310
2022 Q1	$274K	Buy	30,141 +20,031	+198%	+$231K	﹤0.01%	1795
2021 Q4	$207K	Buy	+10,110	New	+$244K	﹤0.01%	1815
2021 Q1	–	Sell	-106,454	Closed	-$2.76M	–	2476
2020 Q4	$2.76M	Buy	+106,454	New	+$1.81M	0.03%	422
2019 Q4	–	Sell	-10,325	Closed	-$53K	–	1795
2019 Q3	$53K	Buy	+10,325	New	+$57.7K	﹤0.01%	1277

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's PACB Position: Q2 2026 in Review

Michael Gelband opened a new position in Pacific Biosciences (PACB) in Q2 2026: 17,004 shares worth $28.6K. The stake represents ﹤0.01% of the portfolio and ranks #1490 among its holdings. This is a return to the name: Michael Gelband previously reported a position in PACB as recently as Q2 2025.

Michael Gelband first reported a position in PACB in Q3 2019 and has held it in 7 quarters since. The position peaked at $2.76M in Q4 2020. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Michael Gelband held 17,004 shares of Pacific Biosciences worth $28.6K as of Q2 2026.
Pacific Biosciences was a new Michael Gelband position in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1490 holding.
Michael Gelband first reported a position in Pacific Biosciences in Q3 2019 and has held it in 7 quarters since.
Michael Gelband's Pacific Biosciences position peaked at $2.76M in Q4 2020.
222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.